跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
hearing loss therapy
首页
药物
hearing loss therapy
hearing loss therapy
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS
EP 4294460 A4
申请人: DECIBEL THERAPEUTICS INC
优先权: 2021
CN
EP
US
WO
4 件公开
WO 2025221253 A1
申请人: DECIBEL THERAPEUTICS INC
优先权: 2024
WO
METHODS AND COMPOSITIONS FOR ADMINISTERING OTOFERLIN DUAL VECTOR SYSTEMS
EP 4665751 A2
申请人: DECIBEL THERAPEUTICS INC
优先权: 2023
CN
EP
US
WO
4 件公开
COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS
EP 4051698 A4
申请人: DECIBEL THERAPEUTICS INC
优先权: 2020
EP
US
WO
4 件公开
EP 3921032 A4
申请人: DECIBEL THERAPEUTICS INC
优先权: 2019
EP
US
4 件公开
US 11660353 B2
申请人: DECIBEL THERAPEUTICS INC
优先权: 2019
US
2 件公开
METHOD FOR TREATING AND MODELLING HEARING LOSS
US 2021130772 A1
申请人: MACKAY MEDICAL COLLEGE
优先权: 2018
US
WO
4 件公开
GENE THERAPY TARGETING COCHLEAR CELLS
EP 4045092 A1
申请人: RES INST NATIONWIDE CHILDRENS HOSPITAL
优先权: 2019
EP
US
WO
3 件公开
GENE THERAPY SYSTEMS AND RELATED METHODS FOR TREATMENT OF HEARING LOSS
EP 4081232 A4
申请人: RESCUE HEARING INC
优先权: 2020
CN
EP
WO
3 件公开
US 20250354134 A1
申请人: RESCUE HEARING INC
优先权: 2019
US
2 件公开
GENE THERAPY FOR HEARING LOSS
EP 4319875 A4
申请人: PERCEIVE BIOTHERAPEUTICS INC
优先权: 2021
EP
US
WO
3 件公开
GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS
EP 4337226 A4
申请人: AKOUOS INC
优先权: 2021
EP
US
WO
3 件公开
US 20250222137 A1
申请人: AKOUOS INC
优先权: 2021
CN
US
2 件公开
CN 117813101 A
申请人: ARCUSE INC
优先权: 2021
CN
DUAL-CARRIER SYSTEM FOR TREATING HEARING DAMAGE, AND USE THEREOF
EP 4527933 A1
申请人: EYE & ENT HOSPITAL OF FUDAN UNIV
优先权: 2022
CN
EP
WO
3 件公开
ADENO-ASSOCIATED VIRUS (AAV) DIRECTED ANTIOXIDATIVE GENE THERAPY FOR THE PREVENTION, AMELIORATION, AND/OR TREATMENT OF HEARING LOSS
EP 4590398 A2
申请人: UNIV RUTGERS
优先权: 2022
EP
US
WO
3 件公开
第 1 / 6 页
上一页
下一页
药物
反馈